Optimizing choice of oral interferon-free treatment for genotype 1 hepatitis C virus using testing for NS5A resistance: a cost-utility analysis from the perspective of the Italian National Health Service

References

• TongMJel-FarraNSReikesARCoRLClinical outcomes after transfusion associated hepatitis CN Engl J Med199533222146314667739682
   PubMed Web of Science ®Google Scholar
• TremoladaFCasarinCAlbertiADragoCTaggerARiberoMLRealdiGLong-term follow-up of non-A, non-B (type C) post-transfusion hepatitisJ Hepatol19921632732811487603
   PubMed Web of Science ®Google Scholar
• TheinHHYiQDoreGJKrahnMDEstimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regressionHepatology200848241843118563841
   PubMed Web of Science ®Google Scholar
• El-SeragHBRudolphKLHepatocellular carcinoma: epidemiology and molecular carcinogenesisGastroenterology200713272557257617570226
   PubMed Web of Science ®Google Scholar
• ChouRHartungDRahmanBWassonNCottrellEBFuRComparative effectiveness of antiviral treatment for hepatitis C virus infection in adults: a systematic reviewAnn Intern Med2013158211412323437439
   PubMed Web of Science ®Google Scholar
• FriedMWShiffmanMLReddyKRPeginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infectionN Engl J Med20023471397598212324553
   PubMed Web of Science ®Google Scholar
• PawlotskyJMNS5A inhibitors in the treatment of hepatitis CJ Hepatol201359237538223567084
   PubMed Web of Science ®Google Scholar
• SarrazinCDvory-SobolHSvarovskaiaEBaseline and Post-Baseline Resistance Analyses of Phase 2/3 Studies of Ledipasvir/Sofosbuvir ± RBVAASLD Liver Meeting2014Boston, MA, USA
   Google Scholar
• SarrazinCDvory-SobolHSvarovskaiaEThe prevalence and the effect of HCV NS5A Resistance-Associated Variants in Patients With Compensated Cirrhosis Treated With Ledipasvir/Sofosbuvir ± RBV50th Annual Meeting EASL2015Vienna, Austria
   Google Scholar
• MarcellusiAVitiRCaponeAMenniniFThe economic burden of HCV-induced diseases in Italy. A probabilistic cost of illness modelEur Rev Med Pharmacol Sci20151991610162026004601
   PubMed Web of Science ®Google Scholar
• LavitzEFlammSYangJRetreatment of patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir based regimens with ledipasvir/sofosbuvir for 24 weeks50th Annual Meeting of the European Association for the Study of the LiverApril 22–26, 2015Vienna, Austria
   Google Scholar
• KwoPGitlinNNahassRSimeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized studyHepatology201664237038026799692
   PubMed Web of Science ®Google Scholar
• LawitzESulkowskiMGhalibRSimeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised studyLancet201438499561756176525078309
   PubMed Web of Science ®Google Scholar
• LawitzEMatusowGDeJesusESimeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2)Hepatology201664236036926704148
   PubMed Web of Science ®Google Scholar
• WesterhoutKTreurMMehnertAPascoeKLadhaIBelseyJA cost utility analysis of simeprevir used with peginterferon + ribavirin in the management of genotype 1 hepatitis C virus infection, from the perspective of the UK National Health ServiceJ Med Econ2015181083884925903830
   PubMed Web of Science ®Google Scholar
• ColomboMFernándezIAbdurakhmanovDSafety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis CGut20146371150115824201995
   PubMed Web of Science ®Google Scholar
• ColomboMPicciotoAAndreonePTreatment of hepatitis C genotype 1 patients with severe fibrosis or compensated cirrhosis: the Italian telaprevir early access program46th A.I.S.F. Annual Meeting 2013/Digestive and Liver Disease 45S2013S1S48
   Google Scholar
• TownsendRMcEwanPKimRYuanYStructural frameworks and key model parameters in cost-effectiveness analyses for current and future treatments of chronic hepatitis CValue Health20111481068107722152176
   PubMed Web of Science ®Google Scholar
• Fernandez-RodriguezCMAlonsoSMartinezSMPeginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting responseAm J Gastroenterol2010105102164217220700116
   PubMed Web of Science ®Google Scholar
• WrightMGrieveRRobertsJMainJThomasHCHealth benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluationHealth Technol Assess200610211113
   Web of Science ®Google Scholar
• SiebertUSroczynskiGRossolSCost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis CGut200352342543212584228
   PubMed Web of Science ®Google Scholar
• Italian National Institute of StatisticsLife tables 2014 Available from: http://dati.istat.it/?lang=en&SubSessionId=a172e556-d13e-44c4-bfef-5ebf67942031&themetreeid=-200Accessed November 30, 2016
   Google Scholar
• YounossiZBoparaiMMcCormickMPriceLLGuyattGAssessment of utilities and health-related quality of life in patients with chronic liver diseaseAm J Gastroenterol200196257958311232711
   PubMed Web of Science ®Google Scholar
• SullivanSJensenDBernsteinDCost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis CAm J Gastroenterol20049981490149615307866
   PubMed Web of Science ®Google Scholar
• KimWRPoteruchaJJHermansJETherneauTMDicksonEREvansRWGrossJBJrCost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis CAnn Intern Med1997127108668749382364
   PubMed Web of Science ®Google Scholar
• BennettWGInoueYBeckJRWongJBPaukerSGDavisGLEstimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis CAnn Intern Med1997127108558659382363
   PubMed Web of Science ®Google Scholar
• SullivanSDCraxiAAlbertiACost effectiveness of peginterferon alfa-2a plus ribavirin versus interferon alfa-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis CPharmacoeconomics200422425726514974875
   PubMed Web of Science ®Google Scholar
• CammaCPettaSEneaMCost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis CHepatology201256385086022454336
   PubMed Web of Science ®Google Scholar
• CammaCPettaSCabibboGCost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis CJ Hepatol201359465866623707373
   PubMed Web of Science ®Google Scholar
• PettaSCabibboGEneaMPersonalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis CDig Liver Dis2014461093694225066806
   PubMedGoogle Scholar
• PettaSCabibboGEneaMCost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis CHepatology20145951692170524691835
   PubMed Web of Science ®Google Scholar
• YounossiZSingerMMirHHenryLHuntSImpact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patientsJ Hepatol201460353053724269472
   PubMed Web of Science ®Google Scholar
• Associazione Italiana per lo Studio del FegatoDocumento di indirizzo dell’Associaziona Italiana per lo Studio del Fegato per l’usi razionale di antivirali diretti di seconda generazione nelle categorie di pazienti affetti da epatitie C cronical ammesse alla rimborsabilita in Italia Available from: http://www.webaisf.org/pubblicazioni/documento-aisf-hcv-2015.aspxAccessed November 30, 2016
   Google Scholar
• Italian National Agency for Regional Healthcare Services (AGENAS) Available from: www.agenas.it/Accessed April, 2013
   Google Scholar
• ShepherdJJonesJHartwellDDavidsonPPriceAWaughNInterferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluationHealth Technol Assess200711111205
   Web of Science ®Google Scholar
• HartwellDJonesJBaxterLShepherdJPeginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluationHealth Technol Assess201115171210
   Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence (NICE)Final Appraisal Determination – Telaprevir for the Treatment of Genotype 1 Chronic Hepatitis C2012 Available from: https://www.nice.org.uk/guidance/ta252/documents/hepatitis-c-genotype-1-telaprevir-final-appraisal-determination-document2Accessed November 30, 2016
   Google Scholar
• Gemeinsamer Bundesausschuss (G-BA)MSD SHARP & DOHME GmbH. Dossier zur Nutzenbewertung. Modul 4. Boceprevir (VIC-TRELIS)2011 Available from: https://www.g-ba.de/informationen/nutzenbewertung/8/Accessed November 30, 2016
   Google Scholar
• DrummondMJeffersonTGuidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ economic evaluation working partyBMJ199631370522752838704542
   PubMed Web of Science ®Google Scholar
• AfdhalNReddyKNelsonDLedipasvir and sofosbuvir for previously treated HCV genotype 1 infectionN Engl J Med2014370161483149324725238
   PubMed Web of Science ®Google Scholar
• ThorlundKDruytsEEl KhouryACMillsEJBudget impact analysis of boceprevir and telaprevir for the treatment of hepatitis C genotype 1 infectionClin Outcomes Res20124349359
   PubMedGoogle Scholar